


## Pomalidomide-PEG3-azide

<b>Cat. No.:</b>	HY-137538
<b>CAS No.:</b>	2267306-15-8
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>24</sub> N <sub>6</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	488.45
<b>Target:</b>	E3 Ligase Ligand-Linker Conjugates
<b>Pathway:</b>	PROTAC
<b>Storage:</b>	-20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 200 mg/mL (409.46 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	2.0473 mL	10.2365 mL	20.4729 mL
		5 mM	0.4095 mL	2.0473 mL	4.0946 mL
	10 mM	0.2047 mL	1.0236 mL	2.0473 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (10.24 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Pomalidomide-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology <sup>[1]</sup> . Pomalidomide-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
<b>IC<sub>50</sub> &amp; Target</b>	Cereblon
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Fangqing Zhang, et al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA